Consumer Protection - Menstrual Hygiene Products - Labeling Requirements
HB1357 requires the Maryland Department of Health to collect, compile, and publicly report annual data on the costs of birth, postpartum care, pregnancy care, and abortion in the State. The bill creates a new part in the Health-General Article, titled “Women’s Health Data Collection and Reporting,” and directs the Department to gather standardized information from hospitals, licensed health care providers, and other entities that provide these services.
The required data includes delivery costs, complications, neonatal care, postpartum follow-up and mental health care, prenatal services, and abortion-related costs such as procedures, follow-up care, abortion pills, abortion pill reversals, and abortion care training programs. The bill also requires tracking Maryland Medical Assistance Program expenditures for chemical and surgical abortions, including associated prescription and pre- and post-operative care. Beginning December 1, 2025, the Department must submit an annual report to the General Assembly and post it publicly, with aggregated statewide and regional data, trend analysis, and any recommendations for improving cost efficiency.
The bill would add new statutory reporting duties to the Maryland Department of Health and create a new data-collection framework in the Health-General Article. It would require hospitals, licensed providers, and other relevant entities to submit standardized cost data, while also obligating the Department to anonymize and de-identify patient information and avoid collecting or reporting anything that would violate privacy laws such as HIPAA. The bill does not directly regulate the provision of reproductive health services, but it would expand state oversight and transparency around the costs of maternal and abortion care and could influence future policy and budget decisions.
Based on the bill text and available context, the measure appears to be framed as a transparency and public-health data initiative rather than a direct service mandate. The stated purpose emphasizes understanding financial impacts, informing policy, and promoting accountability while protecting privacy and dignity. No committee transcript or recorded vote details are provided here, so there is no documented floor or committee debate to indicate broader support or opposition beyond the bill’s introduction and progression.
The most likely points of contention are the inclusion of abortion-related costs and the requirement to track Medical Assistance spending for chemical and surgical abortions, including abortion pill reversals and abortion care training programs. Supporters would likely view the bill as a neutral data-collection and transparency measure for maternal and reproductive health care, while critics may argue that it singles out abortion services, raises privacy or administrative burden concerns, or could be used to shape policy debates about reproductive care. The bill’s privacy safeguards are intended to address confidentiality concerns, but those protections may still be a focus of discussion.